DaVita stock holds above $180 as Q2 2026 earnings and raised outlook support valuation
Published on 08/29/2026 at 12:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
DaVita Inc. (US23918K1088) stock is trading above $180 per share in late August 2026, supported by solid Q2 2026 earnings and a raised full-year adjusted EPS outlook that aligns closely with current analyst expectations as of August 29, 2026.
Q2 2026 earnings beat and updated guidance
Per a recent earnings overview reported on a MarketScreener page for DaVita, the company delivered revenue of $3.55 billion in Q2 2026 for the quarter ended June 30, 2026, slightly ahead of FactSet estimates of $3.50 billion, highlighting stable demand in its core dialysis services business. The same MarketScreener summary also indicates that DaVita now expects full-year 2026 adjusted earnings per share between $14.10 and $15.20, compared with a FactSet consensus of $14.88, signaling a guidance range that brackets and modestly exceeds the current analyst view.
That updated guidance implies that at the midpoint of $14.65, DaVita is targeting adjusted EPS slightly higher than consensus, while still offering a conservative low end at $14.10 and a more optimistic high end at $15.20 for fiscal 2026. The revenue performance in Q2 2026, exceeding estimates by $0.05 billion, adds quantitative support to this outlook and suggests that operational trends during the first half of 2026 have been strong enough for management to raise expectations for the remainder of the year.
The same MarketScreener data set summarizes multiyear revenue and net income figures that show DaVita has grown revenue and net income over recent years, although the snippet is compact and presents values in aggregate form. While those historical figures help frame the trajectory, the key current datapoints for investors are the Q2 2026 revenue of $3.55 billion versus the $3.50 billion estimate and the 2026 adjusted EPS guidance of $14.10 to $15.20, which collectively shape the valuation discussion for DaVita stock as of late August 2026.
Share price, performance and analyst targets
An interactive quote snapshot on a finance portal shows DaVita shares closing at $180.68 on the New York Stock Exchange at 4:00:03 p.m. ET on August 28, 2026, with a gain of 1.01 percent for that session, followed by after-hours trading at $181.60, up another 0.51 percent. The same chart view confirms that DaVita trades in USD under the ticker DVA, and that the late-August 2026 price level around $181 sits well below the average analyst price target cited by MarketScreener.
According to the MarketScreener DaVita overview, the latest closing price is $177.91 and the average analyst price target stands at $218.43, implying potential upside of 22.77 percent from that referenced closing level if the consensus target were reached. That same MarketScreener page also notes that DaVita shares have gained 56.60 percent over the measured period, underscoring a strong run leading into the Q2 2026 earnings update and the upgraded EPS guidance.
For investors, the combination of a Q2 2026 revenue beat of $0.05 billion versus expectations, a full-year 2026 adjusted EPS guidance range that spans from $14.10 to $15.20, and an average price target of $218.43 vs. a recent closing price in the high $170s presents a quantified comparison of operational momentum and valuation headroom. The 22.77 percent difference between the reference closing price of $177.91 and the $218.43 target reflects how the market and analysts collectively view DaVita’s earnings power and growth prospects after the Q2 2026 report.
Earnings yield and sector context
The same commentary set referenced in the search results highlights that DaVita’s earnings yield stands at 8.2 percent, while the broader industry earns 4.7 percent, indicating that DaVita offers an earnings yield that is 3.5 percentage points higher than the sector benchmark. In concrete terms, this means DaVita’s earnings relative to its share price are materially above the average for comparable outpatient and home healthcare companies, reinforcing the notion that the stock’s valuation is supported by robust underlying earnings.
On a practical level, an 8.2 percent earnings yield, when compared to a 4.7 percent industry figure, suggests that DaVita is generating more earnings per dollar of market capitalization than many peers, which could be viewed as either a sign of undervaluation or a recognition of stronger profitability. Combined with the raised adjusted EPS guidance for 2026 and a history of revenue growth culminating in Q2 2026 revenue of $3.55 billion, the earnings-yield data point adds another current metric that investors can use to evaluate DaVita stock as of August 29, 2026.
In the broader outpatient and home healthcare space, such earnings and guidance metrics matter because reimbursement trends, patient volumes, and cost management can shift rapidly, affecting margins and cash flow. DaVita’s ability to post Q2 2026 revenue ahead of estimates and to set a 2026 adjusted EPS range that straddles and slightly exceeds consensus signals operational resilience that may justify the relatively strong earnings yield highlighted by the commentary.
Dialysis network and service offering
DaVita Inc. operates a large network of dialysis centers, providing chronic kidney disease and end-stage renal disease patients with in-center and in-home dialysis treatments, as well as related laboratory, pharmacy, and support services. The company’s revenue base in Q2 2026, as reported by MarketScreener at $3.55 billion, primarily reflects these recurring treatment services, which are supported by long-term patient relationships and contracts with payers including government programs and commercial insurers.
Within this operating model, DaVita focuses on clinical outcomes, patient experience, and cost efficiency across its clinics, leveraging scale to optimize staffing, supply chains, and technology. The Q2 2026 revenue beat of $0.05 billion versus estimates suggests that volumes, reimbursement rates, or mix effects during the quarter were favorable enough to deliver slightly stronger top-line results than the market anticipated.
DaVita also continues to invest in home-based dialysis solutions and digital tools that help patients manage treatment schedules and communicate with care teams. While the search results in this call do not specify individual product names, the overall business model is evident from the earnings and revenue metrics: a recurring-care platform that translates patient volumes and clinical services into multi-billion-dollar quarterly revenue and substantial earnings power, as evidenced by the 2026 adjusted EPS guidance range and the higher earnings yield relative to the industry.
Representative DaVita service
One representative element of DaVita’s business is its in-center hemodialysis service, which provides patients with scheduled treatments several times per week at DaVita-operated clinics. This service underpins a significant portion of the $3.55 billion revenue reported for Q2 2026 and reflects the company’s role as a key provider in the US dialysis market, where consistent treatment adherence and quality of care are essential for patient outcomes.
In-center hemodialysis involves using DaVita-managed equipment, nursing staff, and protocols to deliver blood-filtering treatments that remove waste and excess fluid from the body, substituting for kidney function. The scale of this service line, combined with home and peritoneal dialysis alternatives, supports DaVita’s ability to generate adjusted EPS in the targeted range of $14.10 to $15.20 for full-year 2026, as reported in the MarketScreener earnings summary.
Closing view on DaVita stock
As of August 28, 2026, at 4:00:03 p.m. ET, DaVita shares closed at $180.68 on the NYSE, with after-hours trading indicated at $181.60, according to the interactive chart snapshot. That same chart view provides the most recent completed-session price and confirms the stock’s USD-denominated listing.
Against the backdrop of Q2 2026 revenue of $3.55 billion versus $3.50 billion in estimates, full-year 2026 adjusted EPS guidance of $14.10 to $15.20, an earnings yield of 8.2 percent compared with an industry figure of 4.7 percent, and an average analyst price target of $218.43 with implied upside of 22.77 percent vs. a $177.91 reference close, DaVita stock appears to be trading at a level that reflects strong recent performance but still leaves room for potential valuation convergence if the company delivers on its guidance.
Fact box
Company: DaVita Inc.
ISIN: US23918K1088
Ticker: DVA
Exchange: NYSE
Price (as of August 28, 2026, 4:00 p.m. ET): $180.68 USD
Market cap: not specified in the available snippet
Sector / Industry: Healthcare - Outpatient and home healthcare services
Index membership: S&P 500
